Cyclophosphamide, vincristine, and prednisone followed by tositumomab and iodine-131-tositumomab in patients with untreated low-grade follicular lymphoma: eight-year follow-up of a multicenter phase II study.
J Clin Oncol 28(18):3035-41 (2010) PMID 20458031
The efficacy and safety of cyclophosphamide, vincristine, and prednisone (CVP) followed by tositumomab and iodine-131 ((131)I) -tositumomab therapy were evaluated in a multicenter phase II study in patients with untreated low-grade follicular lymphoma.
DOI: 10.1200/JCO.2009.27.8325
Version: za2963e q8za8 q8zb3 q8zc3 q8zda q8ze1 q8zf4 q8zg0